Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Point-of-care anti-CD19 CAR T for relapsed/refractory CLL/SLL
2022-501686-47-00Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Nov 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of GLPG5301 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Galapagos NV. Primary endpoints: Incidence of (serious) adverse events, including dose-limiting toxicities (DLT) and Best objective response rate per iwCLL response criteria (Lugano classification for Richter's transformation). Started Nov 2022; status: completed.
02
Drugs
GLPG5301
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2022-501686-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501686-47-00.